^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BCD-178 (pertuzumab biosimilar)
i
Other names: BCD-178, BCD 138, BCD-138
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Biocad
Drug class:
HER2 dimerization inhibitor
Related drugs:
7ms
NRG-BR004: Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov)
P3, N=190, Active, not recruiting, National Cancer Institute (NCI) | N=600 --> 190 | Trial completion date: Apr 2024 --> May 2025
Enrollment change • Trial completion date • Metastases
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • IL2 (Interleukin 2)
|
HER-2 positive
|
Tecentriq (atezolizumab) • paclitaxel • docetaxel • Trazimera (trastuzumab-qyyp) • TQB2440 (pertuzumab biosimilar) • BCD-178 (pertuzumab biosimilar)
9ms
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (clinicaltrials.gov)
P3, N=315, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
carboplatin • docetaxel • Trazimera (trastuzumab-qyyp) • goserelin acetate • TQB2440 (pertuzumab biosimilar) • BCD-178 (pertuzumab biosimilar)
10ms
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) (clinicaltrials.gov)
P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2024 --> Jun 2024 | Trial primary completion date: Mar 2024 --> Jun 2024
Trial completion date • Trial primary completion date
|
Trazimera (trastuzumab-qyyp) • TQB2440 (pertuzumab biosimilar) • BCD-178 (pertuzumab biosimilar)
1year
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) (clinicaltrials.gov)
P2, N=35, Active, not recruiting, National Cancer Institute (NCI)
New P2 trial
|
Trazimera (trastuzumab-qyyp) • TQB2440 (pertuzumab biosimilar) • BCD-178 (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar)
1year
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer (clinicaltrials.gov)
P1/2, N=2, Terminated, National Cancer Institute (NCI) | N=12 --> 2 | Recruiting --> Terminated; Inadequate accrual rate
Enrollment change • Trial termination • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
|
HR positive • PIK3CA mutation • PTEN mutation
|
Herceptin (trastuzumab) • Aliqopa (copanlisib) • Trazimera (trastuzumab-qyyp) • TQB2440 (pertuzumab biosimilar) • BCD-178 (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar)
over1year
PREFER: Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer (clinicaltrials.gov)
P3, N=336, Recruiting, Biocad
New P3 trial
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 expression • PGR expression
|
carboplatin • docetaxel • Perjeta (pertuzumab) • BCD-178 (pertuzumab biosimilar)
Share via
